Brief: Beyondspring Says Well On Track To Submit Nda For Plinabulin Cin Program In Q1 2021
10/12/2020 13:00
Dec 10 (Reuters) - BEYONDSPRING:
* BEYONDSPRING - NEW DATA FROM PHASE 3 PROTECTIVE-2 STUDY
106
SHOWS PLINABULIN WITH PEGFILGRASTIM OFFERS GREATER PROTECTION
AGAINST CIN VERSUS. PEGFILGRASTIM ALONE
* BEYONDSPRING - PLINABULIN & PEGFILGRASTIM COMBINATION
REDUCES
ODDS OF HAVING FEBRILE NEUTROPENIA BY 41% VERSUS. PEGFILGRASTIM
ALONE
* BEYONDSPRING - PLINABULIN & PEGFILGRASTIM COMBINATION
REDUCES
INCIDENCE OF PROFOUND NEUTROPENIA BY 53 % VERSUS. PEGFILGRASTIM
ALONE
* BEYONDSPRING - WELL ON TRACK TO SUBMIT NDA FOR PLINABULIN
CIN
PROGRAM IN Q1 2021
Source text for Eikon: urn:newsml:reuters.com:*:nGNX7WLr7x
Further company coverage: [ BYSI.O]
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beyondspring
See all newsBrief: Beyondspring Inc Entered Into Open Market Sale Agreement Under Which Co May Offer And Sell Up To 9.2 Million Ordinary Shares
Brief: Beyondspring Announces FDA Fast Track Designation For Plinabulin In Post-Ici Non-Squamous Nsclc And Strategic Transaction To Advance Global Phase 3 Dublin-4 Trial Toward Planned Interim Analysis
NASDAQ RESUMED AT 12:26 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:21 PM
Brief: Beyondspring Announces Leadership Transition To Deliver Focused Execution On Its Confirmatory Dublin-4 Program And Long-Term Value